Kalypsys announced last week the appointment of David Tiemeier as the company’s chief commercial officer.
Tiemeier joins Kalypsys from Immtech International, where he was vice president of licensing and development. Prior to that, Tiemeier was the vice president of business development at NeoPharm. He has also been employed by Monsanto, Searle, and Pharmacia.
SRI International, and independent non-profit research and development organization, this week announced that Walter Moos will be the new vice president of SRI’s biosciences division.
Most recently, Moos was chairman and CEO of MitoKor. Prior to that, he was a corporate vice president at Chiron, where he had also served as director of chemical therapeutics and vice president of R&D in the technologies division. He holds a PhD in chemistry from the University of California, Berkeley, and received an AB in chemistry from Harvard University.
The Society for Biomolecular Screening has announced that Marc Caron, a professor of cell biology at Duke University Medical Center since 1977, has been awarded the 2005 SBS Achievement Award. Caron will also deliver a keynote speech at SBS’s Annual Conference, to be held Sept. 11-15 in Geneva, Switzerland.
Caron co-founded Norak Biosciences (now Xsira Pharmaceuticals) in 1999, and he was one of the co-developers of that company’s flagship Transfluor fluorescent assay technology. From 1992 to 2004, Caron was an investigator for the Howard Hughes Medical Institute.
Â